ArticleHeliyon2023
Identifying potential biological processes and key targets in COVID-19-associated heart failure.
Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genetic Variants Affect Distinct Metabolic Pathways in Pediatric Multisystem Inflammatory Syndrome and Severe COVID-19.Journal of medical virology · 2025Article
- Unraveling the relevance of SARS-Cov-2 infection and ferroptosis within the heart of COVID-19 patients.Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Novel coronavirus pneumonia (COVID-19) is a new type of viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has spread rapidly and become a global pandemic. Heart failure (HF) is the ultimate period of the development of various cardiovascular diseases. There are several research have found that SARS-CoV-2 infection may induce cardiac complications including enhanced cardiac stress biomarkers and heart failure. Our research aims at identifying underlying biological processes and key targets in COVID-19-associated heart failure via bioinformatics analysis. A total of three heart failure datasets and three COVID-19 datasets were obtained using the Gene Expression Omnibus (GEO) database. Batch effects cross each sample were eliminated with surrogate variable analysis algorithm. Then, we identified key modules of COVID-19 datasets and heart failure datasets through weighted gene co-expression network analysis. HF-associated as well as COVID-19-associated key modules were intersected for determining the shared genes of COVID-19-associated heart failure. The pivotal genes associated with COVID-19-related heart failure were determined by intersecting the shared genes with the HF-associated hub genes selected through WGCNA. Furthermore, we conducted GO as well as KEGG enrichment analysis on shared genes of COVID-19-associated heart failure. Two COVID-19-associated key modules as well as three HF-associated key modules were determined. In addition, eleven shared genes for COVID-19-associated heart failure were determined. In conclusion, our work screened two critical genes, namely PYGM and BLM, which may be possible intervention targets for COVID-19-associated heart failure. According to functional enrichment results, the shared genes of COVID-19-associated heart failure showed high enrichment in starch and sucrose metabolism, homologous recombination, Fanconi anemia pathway, and insulin resistance indicate the probably biological processes linked to COVID-19-associated heart failure. These results provided further insights in possible interventional and therapeutic targets of COVID-19-associated heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.